January 30, 2017
An ARIAD Pharmaceuticals shareholder launched a putative class action in Massachusetts federal court on Saturday over the hedge fund-backed oncology biotech's planned $5.2 billion sale to Japan's Takeda, alleging that the deal is the result of a conflicted sales process and lacks essential disclosures.